



## Research Article

www.ijrap.net



### ROLE OF YOGA ON CARDIC AUTONOMIC FUNCTION TESTS AND COGNITION IN TYPE 2 DIABETES

Rajani Santhakumari Nagothu <sup>\*1</sup>, Indla Yogananda Reddy <sup>1</sup>, Archana R <sup>2</sup>, Rajesh P <sup>1</sup>

<sup>1</sup>Department of Physiology, Mediciti Institute of Medical Sciences, Ghanpur, Medchal, Hyderabad, India

<sup>2</sup>Department of Physiology, Saveetha Medical College, Thandalam, Chennai, India

Received on: 24/08/15 Revised on: 23/09/15 Accepted on: 29/10/15

#### \*Corresponding author

Rajani Santhakumari Nagothu, Assistant Professor, Department of Physiology, MediCiti Institute of Medical Sciences, Ghanpur Village, Medchal Mandal, Ranga Reddy District, Hyderabad, 501-401. India Email: rajaniprabath@gmail.com

DOI: 10.7897/2277-4343.066142

#### ABSTRACT

According to International Diabetic Federation, type 2 diabetic population is on the rise globally and cognitive decline is one of the complications seen in type 2 diabetes. The present study is aimed at exploring the role of regular practice of yoga on cognition in type 2 diabetes and also to study the relation between the cognition and functional status of autonomic nervous system by considering the Cardiac Autonomic (CAN) function tests. Ten type 2 diabetic subjects of both the sex, aged between 35-55 years, who practiced yoga for a period of six months at Yogi Vemana Yoga Research Institute were recruited as test group. Age and sex matched ten type 2 diabetic subjects were recruited as control group; both the group subjects are on oral hypoglycemic agents. Glycosylated hemoglobin concentration was estimated with Bio-Rad instrument, cognition was assessed with Addenbrooke's Cognitive Examination Revised battery and Cardiac autonomic function tests were also conducted. Unpaired student t test was performed and  $p < 0.05$  is considered statistically significant. The mean HbA1c concentration in control and test group subjects is  $7.8 \pm 1.84$  and  $6.9 \pm 0.4\%$  ( $p = 0.03$ ) respectively. Mean cognitive scores in test and control group subjects are  $93 \pm 4.5$  and  $85 \pm 4.0$  ( $p = 0.008$ ) respectively. CAN test results didn't showed any significance between the test and control group. But CAN functions are affected in both the groups. Regular practice of yoga in combination with oral hypoglycemic agents has a positive effect on cognition in type 2 diabetes.

**Key words:** Addenbrooke's cognitive examination-revised, cardiac autonomic function tests, cognition, yoga

#### INTRODUCTION

Cognition is very essential in day to day life, and cognitive decline is one of the complications of type 2 diabetes<sup>1</sup>. Apart from the traditional allopathic medicine, alternative therapies like ayurveda is having a positive role in regulating the plasma glucose levels in type 2 diabetes<sup>2</sup>. Combined practice of yoga with oral hypoglycemic agents have added advantage in management and prognosis of type 2 diabetes over administering the oral hypoglycemic agents alone. CAN tests, specifically parasympathetic CAN tests are more sensitive in identifying the functional status of autonomic nervous system in diabetes<sup>3</sup>. Present study is exploring, the effect of yoga on cognitive decline in type 2 diabetes by modulating the functioning of the autonomic nervous system, which will be indirectly assessed by recording the cardiac autonomic function (CAN) tests. This study is hypothesized that the effect of yoga on cognition in type 2 diabetes is by modulating the balance between parasympathetic and sympathetic nervous system.

#### Aim and objective of the study

- Role of yoga in combination with oral hypoglycemic agents on cognition in type 2 diabetes.
- Effect of yoga on autonomic nervous system in type 2 diabetes, by conducting the cardiac autonomic function tests.

- To find the relation between the cardiac autonomic function tests and cognition in type 2 diabetes.

#### MATERIALS AND METHODS

It is a case control study.

Study was approved by the institutional ethical committee (Ref No: FWA00002084). Ten type 2 diabetic subjects of both the sex, aged between 35-55 years, who practiced yoga for a period of six months in Yogi Vemana Yoga Research Institute, were recruited as test group. Age and sex matched ten type 2 diabetic subjects were recruited as control group after obtaining the written informed consent, both the group subjects are on oral hypoglycemic agents. To minimize the cultural, socio-economical and educational differences, control group subjects were also selected from the same area.

Inclusion criteria; type 2 diabetes, both the sex, age 35-55. Exclusion criteria; type 1 diabetes, type 2 diabetics on insulin therapy, h/o recent major surgeries, smokers and alcoholics.

Test group subjects have practiced specific yogasanas and pranayama over a period of six months, which were listed in table /figure 1 and 2, in yoga institute under the supervision of a qualified yoga expert, 6 days in a week, and 45-60 minutes per day. The set of yogasanas and pranayama included in the study were based on their positive results in diabetic population, which was proved by the earlier studies<sup>4</sup>.

Table 1: List of Yogasanas

S.No	Name of the Yogasana	Duration
1	Dhanurasana	1/2 minute to one minute for the pose being maintained, adding 1/2 minute per week
2	Naukasana	2 - 4 turn of each, the pose being maintained for ten seconds adding one turn each, every fortnight
3	Arthamasthendrasana	¼ minute to one minute for each side, adding ¼ minute per week
4	Bhujangasana	2 - 4 turn of each, the pose being maintained for ten seconds adding one turn each, every fortnight
5	Shavaasana/ Makarasana	3 turn of each, the pose being maintained for 30 seconds

Table 2: List of Pranayama

S.No	Name of the Pranayama	Duration
1	Anuloma-viloma	2-5 minutes
2	Surya anuloma-viloma	5 minutes
3	Chandra anuloma-viloma	5 minutes
4	Nadishuddi pranayama	10 minutes

Glycosylated hemoglobin concentration is estimated with Bio-Rad machine that is based on high performance liquid chromatography (HPLC) principle and HbA1c <6% is non diabetic, between 6-7% considered as good control, >8% requires immediate attention<sup>5</sup>. Cognition was assessed by Addenbrooke's Cognitive Examination - Revised battery (ACE-R), and ACE-R examines the five domains of cognition namely; attention, memory, language, verbal fluency and visuospatial domain. ACE-R was administered by Psychologist in the Psychiatry department. ACE-R contains total score of 100, and scores >88 are considered with normal cognition, between 88-82 are considered with mild cognitive impairment and scores <82 are considered with dementia<sup>6</sup>. Cardiac autonomic (CAN) tests were conducted in the Department of Physiology by a qualified Physiologist. Parasympathetic CAN tests include; Deep Breathing Difference (DBD), Valsalva Ratio (VR) and Postural Tachycardial Index (PTI) and they were conducted with BPL 108 digi ECG machine. Sympathetic CAN tests include; Fall in Systolic Blood Pressure and Rise in Diastolic Blood Pressure and they were conducted

with sphygmomanometer and with hand grip dynamometer. Individual CAN test scores are interpreted as if the score is 0 it means the test is normal, 1 is borderline and 2 is abnormal<sup>7</sup>.

### Statistical Analysis

Statistical analysis was conducted by using Med Calc Statistical Software version 12.7.8 (Med Calc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2014), an unpaired t test was performed to compare the mean difference between test and control group, p value <0.05 was considered as statistically significant.

### RESULTS

Mean HbA1c concentration in test and control groups are 6.9±0.4 and 7.8±1.84 (P=0.03) respectively. Mean ACE-R scores in test and control groups were 93±4.5 and 85±4.0 (P=0.008) respectively, ACE-R scores indicate that the test group subjects are having fair cognition and the control group subjects are having mild cognitive impairment.

Table 3: Results of CAN tests with Mean ± SD

Name of the CAN test	Control group	Test group	P value
DBD	7.0±4.6	7.2±5.02	0.89
VR	1.32±0.17	1.26±0.16	0.52
PTI	0.88±0.07	0.84±0.07	0.50
Fall in SBP	3.6±1.67	6.6±6.8	0.37
Rise in DBP	3.4±3.7	2.0±1.58	0.46
Total CAN scores	5.6±1.40	6.6±1.34	0.23

### DISCUSSION

Glycosylated hemoglobin concentration is more in control group than in the test group subjects. Regular practice of yogasanas and pranayama, mentioned in table 1 and 2 might have increased the glucose disposal in the peripheral tissues in the test group<sup>8</sup>. Control group subjects are having mild cognitive impairment whereas test group subjects are having absolutely normal cognition and these findings are in line with the earlier studies<sup>9</sup>. In type 2 diabetes brain metabolites are altered significantly<sup>10</sup>. The cause for cognitive decline in control group subjects may be the alteration of brain metabolites<sup>11, 12</sup>, and this alteration in brain metabolites is attributed by the hyperglycemia in type 2 diabetes<sup>13-15</sup>. These changes might be by activating the polyol pathway, formation of advanced glycosylated end

products, diacylglycerol activation of protein kinase C or by increasing the glucose shunting through hexosamine pathway<sup>16-19</sup>. CAN tests were more or less similar in both the control and test group subjects as shown in the table 3, and this finding is in contradiction with the earlier research<sup>20</sup>, so the study could not draw any relation between the cognitive decline and CAN tests in type 2 diabetic population.

### CONCLUSION

Combination of regular practice of yoga with oral hypoglycemic agents have better cognitive abilities in type 2 diabetic population over administration of oral hypoglycemic agents alone.

### Limitations of the study

We couldn't conduct the cardiac autonomic function tests before and after the practice of yoga sessions, that might be useful in analyzing the effect of yoga on autonomic functions.

### ACKNOWLEDGEMENT

Research reported in this publication was conducted by scholars at the Fogarty International Center of the NIH training program under Award Number D43 TW 009078. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.

### REFERENECES

1. Rajani S, Reddy IY, KumarS, Archana R. Study of cognition in type 2 diabetes with yoga asana and pranayama. RJPBCS2013; 3(2):1637-41.
2. Bhaktha Geetha, Nayak Shivananda, Shantaram Manjula. Management of newly diagnosed type 2 diabetes by trigonella foenum-graecum. Int J Res Ayurveda & Pharm. 2011;2(4):1231-1234.
3. AK Basu et al., A Study on The Prevalence of Cardiac Autonomic Neuropathy in Type-2 Diabetes in Eastern India, JIACM 2010; 11(3): 190-4.
4. M. Venkata Reddy, K.J.R. Murthy, B.K. Sahay BNP. Yogic therapy. 1st ed. published by Sri MSR. Memorial yoga series 2005; 222.
5. Pack R. Hemoglobin A<sub>1c</sub> Program Instruction Manual. United States, Bio-Rad Laboratories, Inc., Hercules, CA 94547; 1-28.
6. Eneida Mioshi, Kate Dawson, Joanna Mitchell, Robert Arnold, John R. Hodges. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21(11): 1078-1085.
7. Shlomo Melmed. Williams Textbook of Endocrinology. 12<sup>th</sup> ed, Elsevier Saunders philadeiphia, 2012; 1517.
8. Sahay BK. Role of yoga in diabetes. J Assoc Physicians India 2007; 55:121-6.
9. Kate V. Allen, Brian M.frier, Mark W.J. Strachan, The relationship between type 2 diabetes and cognitive function: longitudinal studies and their methodological limitations. Eur J Pharmacol2004; 490(1-3):169-75.
10. Rajani Santhakumari, Indla Yogananda Reddy, Archana R. Effect of type 2 diabetes mellitus on brain metabolites by using proton

magnetic resonance spectroscopy-a systematic review. Int J Pharma Bio Sci 2014 Oct; 5(4):B) 1118-1123.

11. Nagothu R.S, Yogananda Reddy Indla, Archana R, Ravi Varma. Right Dorsolateral Frontal Lobe N-Acetyl Aspartate and Myoinositol Concentration Estimation in Type 2 Diabetes with Magnetic Resonance Spectroscopy. Journal of Clinical and Diagnostic Research, 2015; 9(7):16-19.
12. Pozzessere G, Valle E, Crignis SD, Virginia M, Cordischi, Fattaposta F, et al., Abnormalities of cognitive functions in IDDM revealed by P300 event related potential analysis. Comparison with short latency evoked potentials and psychometric tests. Diabetes 1991; 40: 952-8.
13. Sahin I, Alkan A, Keskin L, Cikim A, Karakas HM, Firat AK et al., Evaluation of in vivo cerebral metabolism on proton magnetic resonance spectroscopy in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Diabetes Complications 2008; 22(4):254-60.
14. Ajilore O, Haroon E, Kumaran S, Darwin C, Binesh N, Mintz J. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology2007; 32:1224-31.
15. Geissler A, Fründ R, Schölmerich J, Feuerbach S, Zietz B. Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy. ExpClinEndocrinol Diabetes2003; 111:421-7.
16. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol 2002; 441:1-14.
17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615-1625.
18. Klein JP, Waxman SG. The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. Lancet Neurol.2003; 2:548-554.
19. Toth C, Schmidt AM, Tuor UI, Francis G, Foniok T, Brussee V, Kaur J, Yan SF, Martinez JA, Barber PA, Buchan A, Zochodne DW. Diabetes, leukoencephalopathy and rage. Neurobiol Dis 2006; 23:445-461.
20. Rajesh P, Gurumurthy Sastry M, Parvathi G. Effect of yoga therapy on anthropometry, metabolic parameters and cardiac autonomic function tests in type 2 diabetes mellitus patients. IJBR 2013; 04:07: 330 - 338.

### Cite this article as:

Rajani Santhakumari Nagothu, Indla Yogananda Reddy, Archana R, Rajesh P. Role of yoga on cardiac autonomic function tests and cognition in type 2 diabetes. Int. J. Res. Ayurveda Pharm. 2015;6(6):764-766 <http://dx.doi.org/10.7897/2277-4343.066142>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IJRAP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJRAP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IJRAP editor or editorial board members.